Dickran Kazandjian, Md

This study tests whether adding linvoseltamab to the standard maintenance drug lenalidomide can eliminate leftover cancer cells in people with multiple myeloma. It includes two groups: those with stable disease and those whose cancer has returned. The goal is to achieve or regain…